Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PARG inhibitor

DRUG CLASS:

PARG inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B
HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation	HER2 Negative Breast Cancer	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B
HR positive + BRCA1 mutation	HER2 Negative Breast Cancer	HR positive + BRCA1 mutation	HER2 Negative Breast Cancer	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B	IDE161 Sensitive: B - Late Trials IDE161 Sensitive : B
HRD	Ovarian Cancer	HRD	Ovarian Cancer	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2
HRD	Breast Cancer	HRD	Breast Cancer	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2	IDE161 Sensitive: C2 – Inclusion Criteria IDE161 Sensitive : C2
HRD	Solid Tumor	HRD	Solid Tumor	PARG inhibitor Sensitive: D – Preclinical PARG inhibitor Sensitive : D	PARG inhibitor Sensitive: D – Preclinical PARG inhibitor Sensitive : D